# Potency Assessment of Active Immunotherapy Products - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/potency-assessment-of-active-immunotherapy-products/c0c49725-86ec-40cb-a98f-19549a1dd4e7

> FDA guidance document: Potency Assessment of Active Immunotherapy Products. Issue date: August 19, 2026. Get complete insights and analysis.

---

## Details

- Title: Potency Assessment of Active Immunotherapy Products
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2026-08-19
- Last Changed: 2026-08-19
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2026-D-8561">FDA-2026-D-8561</a>

## Related Documents

- [Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing](https://www.keypedia.com/guidances/guidance-document/safety-assessment-of-genome-editing-in-human-gene-therapy-products-using-next-generation-sequencing/8bd86906-9b70-4e40-ae4a-dde0c1ea99ca)
- [Expedited Programs for Regenerative Medicine Therapies for Serious Conditions: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for-industry/4c570099-1582-4019-8f81-d0260a2e984c)
- [Potency Assurance for Cellular and Gene Therapy Products](https://www.keypedia.com/guidances/guidance-document/potency-assurance-for-cellular-and-gene-therapy-products/2a9b0d81-9dd5-43cf-994c-ac0df102c216)